ABOS Stock Summary and Trading Ideas (Acumen Pharmaceuticals | NASDAQ:ABOS)

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers. The product pipelines include: ALTITUDE-AD; and INTERCEPT-AD.

Acumen Pharmaceuticals trades on the NASDAQ stock market under the symbol ABOS.

As of September 16, 2026, ABOS stock price declined to $2.61 with 362,193 million shares trading.

ABOS has a beta of 2.05, meaning it tends to be more sensitive to market movements. ABOS has a correlation of 0.09 to the broad based SPY ETF.

ABOS has a market cap of $188.75 million. This is considered a Micro Cap stock.

In the last 3 years, ABOS traded as high as $5.46 and as low as $.86.

The top ETF exchange traded funds that ABOS belongs to (by Net Assets): VTI, VXF, VTWO, DFAS, BUSM.

ABOS has outperformed the market in the last year with a return of +107.1%, while the SPY ETF gained +15.2%. In the last 3 month period, ABOS beat the market returning +11.5%, while SPY returned +0.1%. However, in the most recent 2 weeks ABOS has underperformed the stock market by returning -10.6%, while SPY returned -1.0%.

ABOS support price is $2.75 and resistance is $3.03 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABOS shares will trade within this expected range on the day.